Substituted 2-pyridinemethanol derivatives as potent and selective phosphodiesterase-4 inhibitors. 2003

Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
Merck Frosst Centre for Therapeutic Research, PO Box 1005, Pointe Claire-Dorval, Québec, Canada H9R 4P8. yves_ducharme@merck.com

The synthesis and the phosphodiesterase-4 (PDE4) inhibitory activity of 2-pyridinemethanol derivatives is described. The evaluation of the structure-activity relationship (SAR) in this series of novel PDE4 inhibitors led to the identification of compound 9 which exhibits excellent in vitro activity, desirable pharmacokinetic parameters and good efficacy in animal models of bronchoconstriction.

UI MeSH Term Description Entries
D010726 Phosphodiesterase Inhibitors Compounds which inhibit or antagonize the biosynthesis or actions of phosphodiesterases. Phosphodiesterase Antagonists,Phosphodiesterase Inhibitor,Phosphoric Diester Hydrolase Inhibitors,Antiphosphodiesterases,Inhibitor, Phosphodiesterase
D010847 Picolines A group of compounds that are monomethyl derivatives of pyridines. (From Dorland, 28th ed) Picoline
D006207 Half-Life The time it takes for a substance (drug, radioactive nuclide, or other) to lose half of its pharmacologic, physiologic, or radiologic activity. Halflife,Half Life,Half-Lifes,Halflifes
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D001682 Biological Availability The extent to which the active ingredient of a drug dosage form becomes available at the site of drug action or in a biological medium believed to reflect accessibility to a site of action. Availability Equivalency,Bioavailability,Physiologic Availability,Availability, Biologic,Availability, Biological,Availability, Physiologic,Biologic Availability,Availabilities, Biologic,Availabilities, Biological,Availabilities, Physiologic,Availability Equivalencies,Bioavailabilities,Biologic Availabilities,Biological Availabilities,Equivalencies, Availability,Equivalency, Availability,Physiologic Availabilities
D012453 Saimiri A genus of the family CEBIDAE consisting of four species: S. boliviensis, S. orstedii (red-backed squirrel monkey), S. sciureus (common squirrel monkey), and S. ustus. They inhabit tropical rain forests in Central and South America. S. sciureus is used extensively in research studies. Monkey, Squirrel,Squirrel Monkey,Monkeys, Squirrel,Saimirus,Squirrel Monkeys
D013237 Stereoisomerism The phenomenon whereby compounds whose molecules have the same number and kind of atoms and the same atomic arrangement, but differ in their spatial relationships. (From McGraw-Hill Dictionary of Scientific and Technical Terms, 5th ed) Molecular Stereochemistry,Stereoisomers,Stereochemistry, Molecular,Stereoisomer
D013329 Structure-Activity Relationship The relationship between the chemical structure of a compound and its biological or pharmacological activity. Compounds are often classed together because they have structural characteristics in common including shape, size, stereochemical arrangement, and distribution of functional groups. Relationship, Structure-Activity,Relationships, Structure-Activity,Structure Activity Relationship,Structure-Activity Relationships

Related Publications

Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
December 2013, ChemMedChem,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
May 2015, Bioorganic & medicinal chemistry letters,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
November 2019, Bioorganic chemistry,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
April 1994, Biological & pharmaceutical bulletin,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
November 1995, Journal of medicinal chemistry,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
July 2010, Bioorganic & medicinal chemistry,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
September 2012, Bioorganic & medicinal chemistry letters,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
October 1998, Journal of medicinal chemistry,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
August 2012, Journal of medicinal chemistry,
Yves Ducharme, and Richard W Friesen, and Marc Blouin, and Bernard Côté, and Daniel Dubé, and Diane Ethier, and Richard Frenette, and France Laliberté, and Joseph A Mancini, and Paul Masson, and Angela Styhler, and Robert N Young, and Yves Girard
November 2019, Bioorganic chemistry,
Copied contents to your clipboard!